Market Cap 1.35B
Revenue (ttm) 0.00
Net Income (ttm) -208.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 700,700
Avg Vol 875,394
Day's Range N/A - N/A
Shares Out 60.40M
Stochastic %K 88%
Beta 2.90
Analysts Strong Sell
Price Target $52.91

Company Profile

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and S...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 651 5940
Address:
221 Crescent Street, Building 23 Suite 105, Waltham, United States
OnlyFibs
OnlyFibs Oct. 25 at 1:04 AM
$SYRE - Spyre Therapeutics - Bullish - Golden Cross 50/200sma crossover - Consecutive weeks of buyers - accumulation - Bulls need to claim $25 to confirm more upside - Add to your WL #hovdid
0 · Reply
KingsOnly
KingsOnly Oct. 18 at 3:21 PM
$SYRE warrants price?
0 · Reply
oaksapollo
oaksapollo Oct. 14 at 5:21 PM
$SYRE I don't understand this company. All they're doing is making YTE versions of existing drugs, but there is no IP around YTE, so anyone can go do this. Isn't it a no brainer for the manufacturers of the existing drugs to go make their own YTE versions? For example, why wouldn't Abbvie go make a YTE version of Skyrizi? Nothing is stopping them. I don't quite understand the $1.3B cap. It seems like a zero to me. What does Spyre have that is unique and special?
0 · Reply
Pika_Capital
Pika_Capital Oct. 14 at 2:44 PM
$ORKA $APGE $SYRE reminder
0 · Reply
AlertsAndNews
AlertsAndNews Oct. 14 at 2:41 AM
$SYRE Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock Spyre Therapeutics announced the pricing of its underwritten public offering of 14,864,865 shares of common stock at $18.50 per share, for total gross proceeds of approximately $275 million.
0 · Reply
Pika_Capital
Pika_Capital Oct. 14 at 1:21 AM
$SYRE I expect strong demand during offering as for $APGE Stock is green AH, tomorrow should be interesting
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 13 at 8:33 PM
0 · Reply
DonCorleone77
DonCorleone77 Oct. 13 at 8:04 PM
$SYRE Spyre Therapeutics announces common stock offering, no amount given
0 · Reply
Whiskey1679
Whiskey1679 Oct. 11 at 6:46 PM
Whiskey's Penny Picks out Monday approx. 6:00 am PDT!! Also with China Trump Tariffs a shift in market sentiment on where to invest... Google: best industries to invest today with Trump China Tariffs Defense/Aerospace, Consumer Goods, Healthcare/Telemedicine, Earth Minerals, Energy Steel/Aluminum, Membership clubs seem to be the way to with Trump China Tariffs shifting market sentiment. vehicles. Rare earth mineral miners can benefit from tariffs, which encourage local battery production. Energy: Tariffs on foreign energy sources can boost domestic oil and gas producers. Friday's After Hour Gainers: $FORA $PMAX $VIVK $SYRE $CRML
0 · Reply
FennickTradings
FennickTradings Oct. 11 at 4:08 PM
$SYRE anyone part of the CVR group?
0 · Reply
Latest News on SYRE
Spyre Therapeutics Announces Grants of Inducement Awards

Sep 5, 2025, 4:05 PM EDT - 7 weeks ago

Spyre Therapeutics Announces Grants of Inducement Awards


Spyre Therapeutics: Targeting The Future Of IBD Treatment

Mar 4, 2025, 4:51 AM EST - 8 months ago

Spyre Therapeutics: Targeting The Future Of IBD Treatment


Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Dec 18, 2024, 8:00 AM EST - 11 months ago

Spyre Therapeutics Added to the Nasdaq Biotechnology Index


OnlyFibs
OnlyFibs Oct. 25 at 1:04 AM
$SYRE - Spyre Therapeutics - Bullish - Golden Cross 50/200sma crossover - Consecutive weeks of buyers - accumulation - Bulls need to claim $25 to confirm more upside - Add to your WL #hovdid
0 · Reply
KingsOnly
KingsOnly Oct. 18 at 3:21 PM
$SYRE warrants price?
0 · Reply
oaksapollo
oaksapollo Oct. 14 at 5:21 PM
$SYRE I don't understand this company. All they're doing is making YTE versions of existing drugs, but there is no IP around YTE, so anyone can go do this. Isn't it a no brainer for the manufacturers of the existing drugs to go make their own YTE versions? For example, why wouldn't Abbvie go make a YTE version of Skyrizi? Nothing is stopping them. I don't quite understand the $1.3B cap. It seems like a zero to me. What does Spyre have that is unique and special?
0 · Reply
Pika_Capital
Pika_Capital Oct. 14 at 2:44 PM
$ORKA $APGE $SYRE reminder
0 · Reply
AlertsAndNews
AlertsAndNews Oct. 14 at 2:41 AM
$SYRE Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock Spyre Therapeutics announced the pricing of its underwritten public offering of 14,864,865 shares of common stock at $18.50 per share, for total gross proceeds of approximately $275 million.
0 · Reply
Pika_Capital
Pika_Capital Oct. 14 at 1:21 AM
$SYRE I expect strong demand during offering as for $APGE Stock is green AH, tomorrow should be interesting
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 13 at 8:33 PM
0 · Reply
DonCorleone77
DonCorleone77 Oct. 13 at 8:04 PM
$SYRE Spyre Therapeutics announces common stock offering, no amount given
0 · Reply
Whiskey1679
Whiskey1679 Oct. 11 at 6:46 PM
Whiskey's Penny Picks out Monday approx. 6:00 am PDT!! Also with China Trump Tariffs a shift in market sentiment on where to invest... Google: best industries to invest today with Trump China Tariffs Defense/Aerospace, Consumer Goods, Healthcare/Telemedicine, Earth Minerals, Energy Steel/Aluminum, Membership clubs seem to be the way to with Trump China Tariffs shifting market sentiment. vehicles. Rare earth mineral miners can benefit from tariffs, which encourage local battery production. Energy: Tariffs on foreign energy sources can boost domestic oil and gas producers. Friday's After Hour Gainers: $FORA $PMAX $VIVK $SYRE $CRML
0 · Reply
FennickTradings
FennickTradings Oct. 11 at 4:08 PM
$SYRE anyone part of the CVR group?
0 · Reply
FennickTradings
FennickTradings Oct. 11 at 3:39 PM
$SYRE on 19 august I achieved random dividend, does anyone know why?
0 · Reply
StockScanners
StockScanners Oct. 10 at 1:49 AM
$SYRE keep watch if this holds above 19.50
0 · Reply
x1fisher
x1fisher Oct. 9 at 4:54 PM
QTTB will be the next 5X Biotech squeeze - Massive short interest on a locked up nano float - Cash runaway into 2027 - P2 Data coming up - Bullish chart indicating a historic reversal and was trading over $50 a year ago! $OPEN $ARAI $NEOG $TELO $SYRE ww
1 · Reply
Pika_Capital
Pika_Capital Oct. 9 at 4:25 PM
$ORKA $APGE $SYRE every day of waiting costs you 💰💰
1 · Reply
Money_never_sleep
Money_never_sleep Oct. 9 at 4:08 PM
0 · Reply
Pika_Capital
Pika_Capital Oct. 8 at 4:53 PM
$ORKA $APGE $SYRE reminder 🚀
0 · Reply
Mamma_m1a
Mamma_m1a Oct. 8 at 4:52 PM
$SYRE Bullish Bloomberg:
0 · Reply
Quantumup
Quantumup Oct. 7 at 12:37 PM
Guggenheim reiterated $SYRE Buy-$65-Top Pick after hosting a dinner at UEGW with investors and SYRE's CEO (Cameron Turtle) and CMO (Sheldon Sloan). $JNJ $ABBV Guggenheim said in its note to investors:
0 · Reply
Mamma_m1a
Mamma_m1a Oct. 4 at 8:31 AM
$SYRE Bullish.
0 · Reply
topstockalerts
topstockalerts Sep. 26 at 5:04 PM
Spyre Therapeutics shares rose Friday after Deutsche Bank analyst David Hoang initiated coverage with a Buy rating and $43 price target, signaling significant upside from the previous close of $15.61. Hoang highlighted the company’s potential to lead the inflammatory bowel disease (IBD) space with extended half-life antibodies and fixed-dose combination therapies. Deutsche Bank sees Spyre’s $ 1B market cap as undervaluing its portfolio targeting validated mechanisms (α4β7, TL1A, IL-23) for ulcerative colitis and Crohn’s disease, with potential peak combined sales of $5.7B. Opportunities also exist for TL1A therapies in rheumatic diseases. Analysts noted IBD as an active area for pharmaceutical M&A, referencing positive mid-phase trials from Arena, Telavant, Prometheus, and Morphic. Spyre originated from Fairmount Funds’ Paragon incubator, focused on enhanced biologics for IBD. $SYRE
0 · Reply
JarvisFlow
JarvisFlow Sep. 26 at 11:38 AM
Deutsche Bank has adjusted their stance on Spyre Therapeutics ( $SYRE ), setting the rating to Buy with a target price of 43.
0 · Reply
Biotech_Beast
Biotech_Beast Sep. 19 at 10:33 AM
$SYRE is developing multiple antibodies for ulcerative colitis and testing them as both monotherapy and in combination. Competitors of note include next-gen anti-TL1A developers like $XNCR $ABSI and $ABBV https://seekingalpha.com/article/4824265-intelligent-development-could-make-spyre-therapeutics-stock-best-in-show
0 · Reply